Table 2.
Bovine Colostrum and Its Bioactive Components | Study Type | Name of the Virus | Mechanism of Action | References |
---|---|---|---|---|
Immunoglobulins | In-vitro and In-vivo | HIV | Cross-clade binding and neutralization activity against virus | (78) |
In-vivo | Influenza | Neutralization activity against virus, Increasing NK cell activity and blocking would reduce interleukin 6 production by epithelial cell |
(79, 81) | |
In-vivo | RSV | Inhibition and amelioration the symptom by RSV infection, and enhance the CD8 T cell responses |
(80) | |
Clinical Study | SARS-CoV-2 NCT04643561 |
Activation of a systemic antiviral immunity by targeting the gut immune system. | (87) | |
Oligosaccharides | In-vitro | Campylobacter jejuni Infections | Reduction of the invasion and translocation of enteric infection/virulence effect | (141) |
BC | Clinical trial | Respiratory Tract Infections | Evaluation of the effects of a BC on the early recovery of COVID-19 patients across mild, moderate, and severe categories | (84, 194–198, 200) |
Clinical trial | HIV | Increasing nutritional support and immunity | (83, 202) | |
Clinical trial | SARS-CoV-2 | Neutralization activity against virus Enhancement of resistance to the development of symptoms |
(85, 86, 201) |